Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. AURA
stocks logo

AURA

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.427
-17.79%
--
--
-0.433
-21.21%
--
--
-0.447
-4.96%
Estimates Revision
The market is revising No Change the revenue expectations for Aura Biosciences, Inc. (AURA) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -0.46%.
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-0.46%
In Past 3 Month
Wall Street analysts forecast AURA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AURA is 19.33 USD with a low forecast of 13.00 USD and a high forecast of 23.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast AURA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AURA is 19.33 USD with a low forecast of 13.00 USD and a high forecast of 23.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 6.450
sliders
Low
13.00
Averages
19.33
High
23.00
Current: 6.450
sliders
Low
13.00
Averages
19.33
High
23.00
Evercore ISI
Outperform
initiated
$13
2025-11-25
Reason
Evercore ISI
Price Target
$13
2025-11-25
initiated
Outperform
Reason
Evercore ISI re-initiated coverage of Aura Biosciences with an Outperform rating and $13 price target. Aura uses a photosensitive payload to kill tumor cells in a handful of "underserved," early-stage indications and early data has been "quite supportive," the analyst tells investors. The company's main target populations are earlier than the market is used to considering and with a safe and easy-to-give regimen, Aura could potentially open up these indications and avoid competition, the analyst added.
H.C. Wainwright
Andres Maldonado
initiated
$22
2025-05-28
Reason
H.C. Wainwright
Andres Maldonado
Price Target
$22
2025-05-28
initiated
Reason
H.C. Wainwright analyst Andres Maldonado assumed coverage of Aura Biosciences with a Buy rating and $22 price target. Aura is advancing a tumor-targeted platform that combines localized cytotoxicity with systemic immune activation, anchored by its proprietary virus-like drug conjugate technology, the analyst tells investors in a research note. The firm says the company is positioned to redefine the treatment paradigm in ocular oncology, where early intervention is often avoided due to the destructive nature of existing therapies.
Citizens Capital Markets
Jonathan Wolleben
Buy
Maintains
$21 → $19
2025-03-26
Reason
Citizens Capital Markets
Jonathan Wolleben
Price Target
$21 → $19
2025-03-26
Maintains
Buy
Reason
HC Wainwright & Co.
Edward White
Strong Buy
Maintains
$22 → $25
2025-03-25
Reason
HC Wainwright & Co.
Edward White
Price Target
$22 → $25
2025-03-25
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Edward White
Strong Buy
Reiterates
$22
2025-03-24
Reason
HC Wainwright & Co.
Edward White
Price Target
$22
2025-03-24
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Aura Biosciences Inc (AURA.O) is -3.69, compared to its 5-year average forward P/E of -5.48. For a more detailed relative valuation and DCF analysis to assess Aura Biosciences Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-5.48
Current PE
-3.69
Overvalued PE
-3.29
Undervalued PE
-7.67

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 593.96% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

AURA News & Events

Events Timeline

(ET)
2025-11-13
07:10:03
Aura Biosciences Secures Funding to Support Operations Through First Half of 2027
select
2025-11-13
07:09:32
Aura Biosciences announces Q3 earnings per share of 40 cents, below consensus estimate of 47 cents.
select
2025-08-13 (ET)
2025-08-13
07:08:20
Aura Biosciences reports Q2 EPS (47c) vs (41c) last year
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.0
11-27NASDAQ.COM
Evercore ISI Group Confirms Outperform Rating for Aura Biosciences (AURA)

  • Analyst Recommendation: Evercore ISI Group has reiterated an "Outperform" rating for Aura Biosciences, with a projected one-year price target of $20.66/share, indicating a potential upside of 238.05% from its current price of $6.11/share.

  • Fund Sentiment: There are 236 funds reporting positions in Aura Biosciences, with a slight decrease in ownership by 0.42% over the last quarter, while the average portfolio weight dedicated to AURA has increased by 25.29%.

  • Ownership Breakdown: Major shareholders include Matrix Capital Management (10.90%), Frazier Life Sciences Management (8.03%), and Adage Capital Partners (7.69%), all of which have maintained their positions without change in the last quarter.

  • Market Outlook: The put/call ratio for AURA is 0.01, suggesting a bullish sentiment among investors, while the projected annual revenue for the company is estimated at $6 million, with a non-GAAP EPS of -2.25.

[object Object]
Preview
5.0
11-21Newsfilter
NovaBridge's Visara Division Names Renowned Ophthalmology Experts as Chief Medical Officer and Chair of Scientific Advisory Board to Advance VIS-101

  • Leadership Appointments: NovaBridge Biosciences has appointed Cadmus C. Rich, MD, MBA, as Chief Medical Officer and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board for its subsidiary Visara, enhancing the clinical development expertise for the VIS-101 program.

  • VIS-101 Overview: VIS-101 is a novel bifunctional biologic targeting VEGF-A and ANG-2, with the potential to set a new standard for treating wet age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO), and is expected to be Phase-3-ready by 2026.

  • Expertise of New Leaders: Dr. Rich and Dr. Quezada-Ruiz bring extensive experience in ophthalmology and drug development, with Dr. Rich focusing on clinical functions and Dr. Quezada-Ruiz contributing to the advancement of retinal therapies, including the global approval of VABYSMO®.

  • Company Vision: The appointments reflect NovaBridge's strategic transformation into a global biotech platform, emphasizing its commitment to innovative therapies and the development of VIS-101 as a leading treatment option for retinal diseases.

[object Object]
Preview
5.0
11-20Globenewswire
NovaBridge's Visara Division Names Renowned Ophthalmology Experts as Chief Medical Officer and Chair of Scientific Advisory Board to Advance VIS-101

  • Leadership Appointments: NovaBridge Biosciences has appointed Cadmus C. Rich, MD, MBA, as Chief Medical Officer and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board for its subsidiary Visara, enhancing the clinical development expertise for the VIS-101 program.

  • VIS-101 Overview: VIS-101 is a novel bifunctional biologic targeting VEGF-A and ANG-2, with the potential to set a new standard for treating wet age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO), and is expected to be Phase-3-ready by 2026.

  • Expertise of New Leaders: Dr. Rich and Dr. Quezada-Ruiz bring extensive experience in ophthalmology and drug development, with Dr. Rich focusing on clinical functions and Dr. Quezada-Ruiz having a significant background in retinal therapies and regulatory approvals.

  • Company Vision: The appointments reflect NovaBridge's strategic transformation into a global biotech platform, emphasizing its commitment to innovative therapies and the advancement of VIS-101 to meet unmet medical needs in ophthalmology.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Aura Biosciences Inc (AURA) stock price today?

The current price of AURA is 6.45 USD — it has increased 2.38 % in the last trading day.

arrow icon

What is Aura Biosciences Inc (AURA)'s business?

Aura Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors that aim to preserve organ function. The Company’s lead candidate, bel-sar (AU-011), is in late-stage development for primary choroidal melanoma and in early-stage development in other ocular oncology indications and bladder cancer. It is developing bel-sar as a potential first-line vision-sparing treatment option for early intervention in small choroidal melanoma and/or indeterminate lesions, avoiding the need for radiotherapy and reducing the risk for metastasis for these patients. Bel-sar is a virus-like drug conjugate (VDC) consisting of a human papillomavirus (HPV)-derived virus-like particle (VLP) and a phthalocyanine dye, a light-activated cytotoxic payload. The Company’s platform is designed to enable the targeting of a broad range of solid tumors using VLP, that can be conjugated with drugs or loaded with nucleic acids to create VDCs.

arrow icon

What is the price predicton of AURA Stock?

Wall Street analysts forecast AURA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AURA is 19.33 USD with a low forecast of 13.00 USD and a high forecast of 23.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Aura Biosciences Inc (AURA)'s revenue for the last quarter?

Aura Biosciences Inc revenue for the last quarter amounts to -27.91M USD, increased 20.12 % YoY.

arrow icon

What is Aura Biosciences Inc (AURA)'s earnings per share (EPS) for the last quarter?

Aura Biosciences Inc. EPS for the last quarter amounts to -20189000.00 USD, increased 29.30 % YoY.

arrow icon

What changes have occurred in the market's expectations for Aura Biosciences Inc (AURA)'s fundamentals?

The market is revising No Change the revenue expectations for Aura Biosciences, Inc. (AURA) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -0.46%.
arrow icon

How many employees does Aura Biosciences Inc (AURA). have?

Aura Biosciences Inc (AURA) has 106 emplpoyees as of December 05 2025.

arrow icon

What is Aura Biosciences Inc (AURA) market cap?

Today AURA has the market capitalization of 409.60M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free